These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 32111791)

  • 1. Rivaroxaban
    Kim JH; Seo S; Kim KP; Chang HM; Ryoo BY; Yoo C; Jeong JH; Lee JL; Im HS; Jeong H; Bang Y; Park SR
    In Vivo; 2020; 34(2):829-837. PubMed ID: 32111791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rivaroxaban versus Low-Molecular-Weight Heparin for Venous Thromboembolism in Gastrointestinal and Pancreatobiliary Cancer.
    Lee JH; Oh YM; Lee SD; Lee JS
    J Korean Med Sci; 2019 Jun; 34(21):e160. PubMed ID: 31144482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of rivaroxaban and low molecular weight heparin in the treatment of cancer-associated venous thromboembolism: a Swedish national population-based register study.
    Linder M; Ekbom A; Brobert G; Vogtländer K; Balabanova Y; Becattini C; Carrier M; Cohen AT; Coleman CI; Khorana AA; Lee AYY; Psaroudakis G; Abdelgawwad K; Rivera M; Schaefer B; Giunta DH
    J Thromb Thrombolysis; 2024 Aug; 57(6):973-983. PubMed ID: 38735015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer.
    Streiff MB; Milentijevic D; McCrae K; Yannicelli D; Fortier J; Nelson WW; Laliberté F; Crivera C; Lefebvre P; Schein J; Khorana AA
    Am J Hematol; 2018 May; 93(5):664-671. PubMed ID: 29396864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison Between Non-vitamin K Antagonist Oral Anticoagulants and Low-Molecular-Weight Heparin in Asian Individuals With Cancer-Associated Venous Thromboembolism.
    Chen DY; Tseng CN; Hsieh MJ; Lan WC; Chuang CK; Pang ST; Chen SW; Chen TH; Chang SH; Hsieh IC; Chu PH; Wen MS; Chen JS; Chang JW; See LC; Huang WK
    JAMA Netw Open; 2021 Feb; 4(2):e2036304. PubMed ID: 33533929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the Efficacy and Safety of Rivaroxaban and Low Molecular Heparin in Preventing Venous Thromboembolism in Inpatient Cancer Patients.
    Wu S; Guan C; Chang S; Wang C; Zhang J
    Ann Pharmacother; 2024 Mar; 58(3):214-222. PubMed ID: 37312538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of cancer-associated venous thromboembolism].
    Di Nisio M
    G Ital Cardiol (Rome); 2018 Sep; 19(9 Suppl 1):7S-12S. PubMed ID: 30284557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of rivaroxaban and dalteparin for the long-term treatment of venous thromboembolism in patients with gynecologic cancers.
    Lee JH; Lee JH; Jo KW; Huh JW; Oh YM; Lee JS
    J Gynecol Oncol; 2020 Jan; 31(1):e10. PubMed ID: 31789000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis.
    Giustozzi M; Agnelli G; Del Toro-Cervera J; Klok FA; Rosovsky RP; Martin AC; Herold J; Tzoran I; Szmit S; Bertoletti L; Becattini C; Huisman MV
    Thromb Haemost; 2020 Jul; 120(7):1128-1136. PubMed ID: 32365386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rivaroxaban Versus Low-Molecular-Weight Heparins in a Broad Cohort of Patients With Cancer-Associated Venous Thromboembolism: An Analysis of the OSCAR-US Program.
    Caroti KS; Khorana AA; Becattini C; Lee AYY; Ekbom A; Carrier M; Cohen AT; Brescia C; Abdelgawwad K; Psaroudakis G; Rivera M; Schaefer B; Brobert G; Coleman CI
    Clin Appl Thromb Hemost; 2023; 29():10760296231189282. PubMed ID: 37583314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of recurrence and bleeding in patients with cancer-associated venous thromboembolism treated with rivaroxaban: A nationwide cohort study.
    Søgaard M; Nielsen PB; Skjøth F; Kjaeldgaard JN; Larsen TB
    Cancer Med; 2019 Mar; 8(3):1044-1053. PubMed ID: 30767432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct oral anticoagulants for venous thromboembolism in cancer patients: a systematic review and network meta-analysis.
    Wu S; Lv M; Chen J; Jiang S; Chen M; Fang Z; Zeng Z; Qian J; Xu W; Guan C; Zhang J
    Support Care Cancer; 2022 Dec; 30(12):10407-10420. PubMed ID: 36318341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent thromboembolism, bleeding, and mortality in Asian patients with venous thromboembolism receiving different oral anticoagulants: A nationwide analysis.
    Lee MC; Liao CT; Feng IJ; Yu T; Chang WT; Shih MF; Su HC; Toh HS
    Medicine (Baltimore); 2022 Sep; 101(37):e30412. PubMed ID: 36123930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low molecular weight heparin versus rivaroxaban in the treatment of venous thromboembolism in gastrointestinal malignancies.
    Choe HK; De Sancho MT; Kim SS; Dai T; Shah MA
    Blood Coagul Fibrinolysis; 2018 Mar; 29(2):227-230. PubMed ID: 29389673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison between direct factor Xa inhibitors and low-molecular-weight heparin for efficacy and safety in the treatment of cancer-associated venous thromboembolism: A meta-analysis.
    Yang M; Li J; Sun R; Wang Y; Xu H; Yang B; Wu X; Yu L
    J Cancer Res Ther; 2019; 15(7):1541-1546. PubMed ID: 31939435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of unfractionated heparin versus low-molecular-weight heparin and fondaparinux for pharmacologic venous thromboembolic prophylaxis in critically ill patients with cancer.
    Van Matre ET; Reynolds PM; MacLaren R; Mueller SW; Wright GC; Moss M; Burnham EL; Ho PM; Vandivier RW; Kiser TH
    J Thromb Haemost; 2018 Dec; 16(12):2492-2500. PubMed ID: 30347498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of rivaroxaban or low-molecular-weight heparin in non-major orthopedic surgery: a meta-analysis of randomized controlled trials.
    Zhu L; Zhu B; Bing P; Qi M; He B
    J Orthop Surg Res; 2024 Sep; 19(1):609. PubMed ID: 39342255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).
    Young AM; Marshall A; Thirlwall J; Chapman O; Lokare A; Hill C; Hale D; Dunn JA; Lyman GH; Hutchinson C; MacCallum P; Kakkar A; Hobbs FDR; Petrou S; Dale J; Poole CJ; Maraveyas A; Levine M
    J Clin Oncol; 2018 Jul; 36(20):2017-2023. PubMed ID: 29746227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Efficacy of Novel Oral Anticoagulants vs Low Molecular Weight Heparin for Thromboprophylaxis in Large-Volume Liposuction and Body Contouring Procedures.
    Morales R; Ruff E; Patronella C; Mentz H; Newall G; Hustak KL; Fortes P; Bush A
    Aesthet Surg J; 2016 Apr; 36(4):440-9. PubMed ID: 26961988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence.
    Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
    Clin Ther; 2016 Mar; 38(3):478-93.e1-16. PubMed ID: 26922297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.